Catastrophic haemorrhage in military major trauma patients: a retrospective database analysis of haemostatic agents used on the battlefield. Winstanley et al.

[ 11 ] Winstanley M, Smith JE, Wright C.  

J R Army Med Corps 2018;0:1-5.

A retrospective database analysis of 3792 cases of catastrophic hemorrhage in military major trauma patients on the battlefield was conducted. When comparing patients, 317, who had a hemostatic dressing applied (either Celox (OMNI-STAT), Hemcon or Quikclot) versus no hemostatic agent, results showed there was a 7% improvement in survival. Celox (OMNI-STAT) was the only individual hemostatic dressing that was associated with a statistically significant improvement in survival, which was most apparent in the more severely injured.

Abstract

Objectives Catastrophic haemorrhage is a leading cause of morbidity and mortality in trauma, in both military and civilian settings. There are numerous studies looking at the effectiveness of different haemostatic agents in the laboratory but few in a clinical setting. This study analyses the use of haemostatic dressings used in patients injured on the battlefield and their association with survival.

Method A retrospective database review was undertaken using the UK Joint Theatre Trauma Registry from 2003 to 2014, during combat operations in Iraq and Afghanistan. Data included patient demographics, the use of haemostatic dressings, New Injury Severity Score (NISS) and patient outcome.

Results Of 3792 cases, a haemostatic dressing was applied in 317 (either Celox, Hemcon or Quickclot). When comparing patients who had a haemostatic dressing applied versus no haemostatic agent, there was a 7% improvement in survival. Celox was the only individual haemostatic dressing that was associated with a statistically significant improvement in survival, which was most apparent in the more severely injured (NISS 36–75).

Conclusion We have shown an association between use of haemostatic agents and improved survival, mostly in those with more severe injuries, which is particularly evident in those administered Celox. This supports the continued use of haemostatic agents as part of initial haemorrhage control for patients injured in conflict and suggests that civilian organisations that may need to deal with patients with similar injury patterns should consider their use and implementation.

Read More

Contact

Omni-stat Medical Inc

New York – SoHo – Hudson Square,
101 Avenue of the Americas,
8th and 9th Floors,
New York, NY 10013,
USA

Proud to be an Official Partner of

Stop the Bleed Logo
Inquire Here

General Inquiries

Please leave us your details as below and submit or send us an e-mail to: info@omni-stat.com

Product Inquiry

Please leave us your details as below and submit or send us an e-mail to: info@omni-stat.com

Order Inquiry

Please leave us your details as below and submit or send us an e-mail to: info@omni-stat.com

OMNI-STAT® Clinical and Scientific Monograph

Please leave us your details as below and submit or send us an e-mail to: info@omni-stat.com

Request a Product Demonstration

Please leave us your details as below and submit or send us an e-mail to: info@omni-stat.com

Please select a valid form.

Request an In-Service

Please leave us your details as below and submit or send us an e-mail to: info@omni-stat.com

Please select a valid form.

This website uses Cookies to improve your browsing experience. View Cookies Policy

I'm fine with this